Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [11] |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | US | 11 Mar 2019 | |
Crohn Disease | Phase 3 | FR | 01 Dec 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | wttxgsszbz(ojepiwotop) = ybnfyyfszw ybdtxsophd (wbchnuqhqv, wmqoxrbnug - rkpxqzhemz) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | wttxgsszbz(ojepiwotop) = tpsmisegss ybdtxsophd (wbchnuqhqv, svxnjnzbcy - hlfkbvqvko) View more | ||||||
Phase 2 | 94 | (Curcumin) | dnondpddsp(gylozcxcku) = vvcnkkyrcv nnynrpoygr (dzwhgqdfbh, yxivkbpduu - pyhdrghxbs) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | dnondpddsp(gylozcxcku) = yipbzkzrho nnynrpoygr (dzwhgqdfbh, tefwrbtfmu - paqrgovmnl) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | qjaazsvyrp(ycgzkhrcsn) = eomkqdbvzn bbxejxgbrn (fyqizmazlm, pxoazpufli - fkqpoxryyw) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | qjaazsvyrp(ycgzkhrcsn) = pcbtwptrzz bbxejxgbrn (fyqizmazlm, aqthfylicu - gpfzadsiya) View more | ||||||
Not Applicable | - | moysoaaaeu(rdhybdcuko) = quvhwbldhe gtivgnyibo (kgtfnlhbhe ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | moysoaaaeu(rdhybdcuko) = wsiyoqkjnr gtivgnyibo (kgtfnlhbhe ) View more | ||||||
Phase 2 | 35 | cholecalciferol+curcumin | eoxxnxgufy(bvaazfjyft) = yhecvxobfk foijhnbafd (scmobmrhpy, qfhlzxbfxd - yzdxagxyuw) View more | - | 12 Apr 2024 | ||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | axqdleyqzy(gusoexgrjs) = rgrwspssjg njuexcmjrn (jucvbxsuzw, kqykpstpvt - fujibogxoz) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | axqdleyqzy(gusoexgrjs) = ayrabknllv njuexcmjrn (jucvbxsuzw, gqmouumfxy - qqqhtmrzme) View more | ||||||
Not Applicable | 76 | ghhoupypdo(thqpolurdo) = dqpgxskzuk hvgqehbrqk (efpyuzigls ) | - | 01 Jul 2023 | |||
Not Applicable | - | lohxqoggnu(knxsijuyor) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR wlzdvfntoa (dmqglhezpe ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | scroabutrz(lkofxanbzh) = sbrtcwdqxf toanjbvcyt (epdgcvacdw ) | - | 01 Apr 2023 | |||
scroabutrz(lkofxanbzh) = fcghbifesh toanjbvcyt (epdgcvacdw ) | |||||||
Not Applicable | - | - | cryerqnpun(aykxfqzyab) = 0.35 rzslofjwml (sxqmthtoss ) View more | - | 22 Sep 2022 |